Title:Effects of Alkoxy Chain Length and 1-Hydroxy Group on Anticolorectal
Cancer Activity of 2-Bromoalkoxyanthraquinones
Volume: 19
Issue: 9
Author(s): Nurhaliza Wati Mekzali, Cheok Wui Chee, Iskandar Abdullah*, Yean Kee Lee, Nurshamimi Nor Rashid, Vannajan Sanghiran Lee, Rozana Othman, Najihah Mohd Hashim and Chin Fei Chee*
Affiliation:
- Department of Chemistry, Drug Design and Development Research Group (DDDRG), Faculty of Science, Universiti
Malaya, Kuala Lumpur, 50603, Malaysia
- Centre for Natural Products and Drug Discovery (CENAR), Universiti Malaya, Kuala
Lumpur, 50603, Malaysia
- Nanotechnology and Catalysis Research Centre, Institute for Advanced Studies, Universiti
Malaya, Kuala Lumpur, 50603, Malaysia
Keywords:
Alizarin, alkylation, antiproliferation, colorectal cancer, 2-hydroxyanthraquinone, in silico, side chain.
Abstract:
Background: KRAS and p53 are two of the most common genetic alterations associated
with colorectal cancer. New drug development targeting these mutated genes in colorectal cancer
may serve as a potential treatment avenue to the current regimen.
Objective: The objective of the present study was to investigate the effects of alkoxy chain length
and 1-hydroxy group on anticolorectal cancer activity of a series of 2-bromoalkoxyanthraquinones
and corroborate it with their in silico properties.
Methods: In vitro anticancer activity of 2-bromoalkoxyanthraquinones was evaluated against
HCT116, HT29, and CCD841 CoN cell lines, respectively. Molecular docking was performed to
understand the interactions of these compounds with putative p53 and KRAS targets (7B4N and
6P0Z).
Results: 2-Bromoalkoxyanthraquinones with the 1-hydroxy group were proven to be more active
than the corresponding counterparts in anticancer activity. Among the tested compounds, compound
6b with a C3 alkoxy chain exhibited the most promising antiproliferation activity against HCT116
cells (IC50 = 3.83 ± 0.05 μM) and showed high selectivity for HCT116 over CCD841 CoN cells (SI =
45.47). The molecular docking reveals additional hydrogen bonds between the 1-hydroxy group of
6b and the proteins. Compound 6b has adequate lipophilicity (cLogP = 3.27) and ligand efficiency
metrics (LE = 0.34; LLE = 2.15) close to the proposed acceptable range for an initial hit.
Conclusion: This work highlights the potential of the 1-hydroxy group and short alkoxy chain on
anticolorectal cancer activity of 2-bromoalkoxyanthraquinones. Further optimisation may be warranted
for compound 6b as a therapeutic agent against colorectal cancer.